UPDATE: Goldman Sachs Initiates Coverage on ViroPharma at Neutral
According to Goldman Sachs, ViroPharma (NASDAQ: VPHM) coverage is initiated with a Neutral rating.
Goldman Sachs said that it initiates on ViroPharma (VPHM) with a Neutral rating and a 12-month price target of $26. VPHM is a profitable, mid-cap biotechnology company with three marketed drugs. “We view VPHM as an attractive growth story in mid-cap biotech but outstanding questions on expansion of manufacturing capacity and limited pipeline catalysts over the next several quarters keep us at Neutral.”
ViroPharma closed yesterday at $27.02.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.